Abstract
Glioblastoma (GB) is the most common and aggressive neoplastic brain tumor, and its treatment has proved to be a challenge.
For decades its therapy has been based on the use of temozolomide (TMZ), but the survival rate remains low. However, the
discovery of the cytotoxic properties of ferrocene compounds (Fc) has suggested new approaches in the use of these ferric
structures coupled to chemotherapeutics in the treatment of several cancers.